Additional file 5 of Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence

Additional file 5: Figure S3. Risk for cardiovascular and kidney outcome in SGLT2i initiators compared to oGLAs in the entire cohort, during the sOT follow up definition. Event rates are presented as number of events per 100 person years of follow up. In black—the unadjusted model; and in grey—the model adjusted to baseline eGFR (as continuous variable) and UACR (as categorical variable). SGLT2i = sodium/glucose cotransporter-2 inhibitors; oGLAs = other glucose lowering agents; sOT = strict on treatment; hHF = hospitalization for heart failure; ACM =all-cause mortality; MI = myocardial infract; eGFR = estimated glomerular filtration rate; ESKD = end stage kidney disease; ER = event rate